Patients with advanced DD had lower maximal METs achieved compared with those with normal diastolic function (OR 3.18(1.96 to 5.14) for stage 1 versus normal, and 3.21(1.89 to 5.43) for stage ≥2 versus normal, p<0.0001 for both).
Surprisingly, worse kidney function or CKD stage ≥3 was also associated with long-term survival.
Lung tissue of former smokers (defined as quitting smoking for at least one year before surgery) with normal lung function or GOLD stage IV COPD was obtained from patients undergoing surgery for resection for pulmonary carcinoma or lung transplantation.
This variation makes it virtually impossible to find baseline values of these biomarkers falling within the normal range, even in ICU patients with normal renal function or early stage CKD.
The goal of this study was to determine the incidence of drug-associated AKI using the RIFLE (Risk, Injury, Failure, Loss of kidney function, or End-Stage kidney disease) criteria in NH residents.
The patients were aged >20 years with normal renal function or with stages 1 4 CKD.
Inclusion criteria were patients aged >20 years with normal renal function or with stages 1~4 CKD, excluding conditions such as acute renal failure, inherited kidney diseases, nephritic syndrome, cancer, and long-term use of steroid.
Patients who met any level of risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function, or end-stage kidney disease (RIFLE) criteria were defined as having cisplatin- or carboplatin-induced nephrotoxicity in this study [ 31].
The urinary TGF-β1 excretion was significantly lower but still higher than normal in patients with crescentic nephritis who showed improvement of renal function with immunosuppressive treatment compared to those who showed no improvement and had either stabilized renal function or end-stage renal disease after treatment (376 ± 84 vs. 930 ± 126 ng/24 h, p < 0.01) (Fig. 3).
